Navigation Links
Orphan Drugs - Global Strategic Business Report
Date:12/4/2013

DUBLIN, December 4, 2013 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/9n9pzh/orphan_drugs) has announced the addition of the "Orphan Drugs - Global Strategic Business Report" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)

This report analyzes the worldwide markets for Orphan Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Europe, Japan, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets.

The report profiles 113 companies including many key and niche players such as:

- AbbVie Inc.
- Actelion Pharmaceuticals Ltd.
- Amgen Inc.
- AstraZeneca plc
- Bayer HealthCare AG
- Biogen Idec Inc.
- Bristol-Myers Squibb Company
- Boehringer Ingelheim GmbH
- Celgene Corporation
- CEL-SCI Corporation
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc
- Johnson & Johnson
- Merck & Co. Inc.
- Merck Serono International S.A.
- Novartis AG
- Pfizer Inc.
- Recordati S.p.A.
- Orphan Europe
- Sanofi SA
- Genzyme Corporation.


Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.

For more information visit http://www.researchandmarkets.com/research/9n9pzh/orphan_drugs

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals



'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Kinex Pharmaceuticals Announced that the U.S. Food and Drug Administration has Granted Orphan Drug Status to KX02 for the Treatment of Gliomas
2. Agility-PSR Wins "Best Contract Research Organization" in the 2013 ROAR Awards at the 4th Annual World Orphan Drug Conference in Geneva
3. CMC Contrast Granted Orphan Drug Designation by the FDA for its Liver Specific MRI Contrast Media CMC-001
4. Lumena Pharmaceuticals Receives Positive Opinion for Orphan Drug Designation in the European Union for LUM001 in Four Rare Liver Diseases
5. FDA Designates MST-188 As An Orphan Drug For Treatment Of Acute Limb Ischemia
6. U.S. FDA Grants Orphan Drug Designation for KaloBios KB001-A in Treatment of Cystic Fibrosis Patients
7. FDA Grants Orphan Drug Designation to Omeros OMS824 for Huntingtons Disease
8. Lumena Pharmaceuticals Receives Orphan Drug Designation from US Food & Drug Administration for LUM001 in Four Rare Liver Diseases
9. Bayers Investigational Drug Riociguat Granted FDA Orphan Drug Designation for Treatment of Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension
10. NovelMed Awarded NIH Fast Track SBIR Grant for $1.43 Million to Advance Development of its Anti-Complement Antibody for Orphan Disease
11. Orphan Drugs for Cancer: R&D and Market 2013-2023
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... 27, 2016 Hutchison China ... focused on the highly lucrative global oncology and ... of potential first-in-class or best-in-class tyrosine kinase inhibitor ... with strategic partners. HCM,s profitable Chinese healthcare business ... We expect progress of the mid-to-late-stage pipeline during ...
(Date:5/26/2016)... , May 26, 2016 A ... growth is the emergence of new treatments. Cardax, a ... for osteoarthritis treatment. The therapy is expected to fulfil ... Research UK is conducting studies to develop new treatments ... where the genes involved in osteoarthritis are being investigated, ...
(Date:5/25/2016)... 25, 2016 According to a ... (3D, 2D, 4D), by Therapeutic Area (Oncology, Cosmeceutical/Plastic Surgery), ... (Medical Device Manufacturers, Hospitals/ Clinics) - Forecast to 2021", ... Animation Market for the forecast period of 2016 to ... Million by 2021 from USD 117.3 Million in 2016, ...
Breaking Medicine Technology:
(Date:5/28/2016)... ... May 28, 2016 , ... "Color Grading media can be time ... preset onto their media," said Christina Austin - CEO of Pixel Film Studios. ... and easily add stylish color grades to their footage. A LUT is a Lookup ...
(Date:5/28/2016)... ... ... of the city where’s it’s easy to spot the neon lights of chains serving fast ... diners with a taste for real food. , On May 13, the Best ... urban casual restaurant focusing on dishes made by hand with wholesome, organic ingredients that are ...
(Date:5/27/2016)... ... May 27, 2016 , ... Two director-level employees of Horizon ... to Women and Industry (TWIN) 2016 honorees. The award recognizes businesswomen who excel ... year, Geri Boone, Director of the MLTSS (Managed Long-Term Services and Supports) Program at ...
(Date:5/27/2016)... ... May 27, 2016 , ... With over 60 percent of acute stroke ... a sustainable product to aid in the rehabilitation process has steadily increased. Ekso Bionics ... individuals with hemiplegia due to stroke. , Ekso Bionics has now received clearance from ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... educate the many who are unaware of the plight of aphasia. In collaboration ... within the “Stroke Awareness” campaign. , The link between stroke and aphasia is ...
Breaking Medicine News(10 mins):